Plasma TGF-β1-related survival of postmenopausal metastatic breast cancer patients

Clinical and Experimental Metastasis

Volumn 21, Issue 7, 2005, Pages 581-585

  Nikolic Vukosavljevic D ^a   Todorovic Rakovic N ^a   Demajo, M ^b   Ivanovic V ^b   Neskovic B ^a   Markicevic M ^a   Neskovic Konstantinovic Z ^a  

^a INSTITUTE FOR ONCOLOGY AND RADIOLOGY OF SERBIA   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

ER PR status; Metastatic breast cancer; Postmenopausal patients; Survival; TGF 1

Indexed keywords

ESTRADIOL; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; RADIOLIGAND; TRANSFORMING GROWTH FACTOR BETA1; TGFB1 PROTEIN, HUMAN; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; BREAST CANCER; CANCER RISK; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIGH RISK POPULATION; HUMAN; METASTASIS; POSTMENOPAUSE; PROGNOSIS; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; BLOOD; BREAST TUMOR; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; RADIOASSAY; SURVIVAL;

BREAST NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESTRADIOL; FEMALE; HUMANS; NEOPLASM METASTASIS; POSTMENOPAUSE; RADIOLIGAND ASSAY; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL ANALYSIS; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

EID: 14544274632     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10585-004-4978-1     Document Type: Article

References (20)

1. Siegel PM, Massague J. Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer. Cancer 2003; 3: 807-20.
2. Derynck R, Akhurst RJ, Balmain A. TGF-β signaling in tumor suppression and cancer progression. Nat Genet 2001; 29: 117-29.
3. Ivanović V, Todorović-Raković N, Demajo M et al. Elevated plasma levels of transforming growth factor-β1 (TGF-β1) in patients with advanced breast cancer: Association with disease progression. Eur J Cancer 2003; 39: 454-61.
4. EORTC Breast Cancer Cooperative Group. Revision of the standards for the assessment of hormone receptors in human breast cancer. Eur J Cancer 1980; 9: 1513-5.
5. Lowry OH, Rosebrough NJ, Farr AL et al. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265-75.
6. Romain S, Laine BC, Martin PM et al. On behalf of the EORTC Receptor Study Group. Steroid receptor distribution in 47892 breast cancers. A collaborative study of 7 European laboratories. Eur J Cancer 1995; 31(A): 411-7.
7. EORTC Breast Cancer Cooperative Group. Manual for Clinical Research in Breast Cancer. Leuven, 1991.
8. Stockler M, Wilcken NRC, Ghersi D et al. Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer. Cancer Treat Rev 2000; 26: 151-68.
9. Stearns V, Yamauchi H, Hayes DF. Circulating tumor markers in breast cancer: Accepted utilities and novel prospects. Breast Cancer Res Treat 1998; 52: 239-59.
10. Stewart AJ, Westley BR, May FEB. Modulation of the proliferative response of breast cancer cells to growth factors by oestrogen. Br J Cancer 1992; 66: 640-8.
11. Tang B, Vu M, Booker T et al. TGF-β switches from tumor suppressor to prometastatic factor in a model of breast cancer progression. J Clin Invest 2003; 112: 1116-24.
12. Osborne CK. Steroid hormone receptors in breast cancer management. Breast Cancer Res Treat 1998; 51: 227-38.
13. Encarnacion CA, Ciocca DR, McGuire WL et al. Measurement of steroid hormone receptors in breast cancer patients on tamoxifen. Breast Cancer Res Treat 1993; 26: 237-46.
14. Arteaga CL, Tandon AK, Von Hoff DV et al. Transforming growth factor beta: Potential autocrine growth inhibitor of estrogen receptor-negative human breast cancer cells. Cancer Res 1988; 16: 2231-42.
15. Amoils KD, Bezwoda WR. TGF-β1 mRNA expression in clinical breast cancer and its relationship to ER mRNA expression. Breast Cancer Res Treat 1997; 42: 95-101.
16. Fey MF, Brunner KW, Sonntag RW. Prognostic factors in metastatic breast cancer. Cancer Clin Trials 1981; 4: 237-47.
17. Hietanen P, Miettinen M, Makinen J. Survival after first recurrence in breast cancer. Eur J Cancer Clin Oncol 1986; 22: 913-8.
18. Knabbe C, Lippman ME, Wakefield LM et al. Evidence that transforming growth factor beta is a hormonally regulated negative growth factor in human breast cancer cells. Cell 1987; 48: 417-28.
19. Hering S, Surig D, Freystact D et al. Regulation of transforming growth factor beta by sex steroids. Horm Metab Res 1995; 27: 345-51.
20. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor b in human disease. N Engl J Med 2000; 342: 1350-8.